reason report
bottom line recent medacorp survey ob/gyn
physician gnrh gonadotropin releas hormon
antagonist class continu suggest multi-billion-dollar market
endometriosi em uterin fibroid uf could support
sale three product orilissa relugolix
linzagolix one alreadi market two
late stage develop initi coverag myov today
link outperform rate price target reiter
outperform rate price target also reiter
outperform rate obsv price target detail
takeaway survey chang model found
insid note
although initi uptak orilissa slow potenti
due access hurdl continu believ overal gnrh
market grow recent cut
sale guidanc orilissa reiter
guidanc sale believ peak sale potenti
market achiev despit slow initi uptak
physician feedback posit far face
signific hurdl access believ improv coverag
critic ramp focus conjunct
awar build market take time activ given
lack new treatment decad invest
significantli promot campaign improv patient awar
direct-to-consum dtc advertis product sampl
level awar adopt still vari significantli across
physician payer access patient awar improv
addit competitor enter market durat use
expand long-term safeti data becom avail physician gain
experi overal posit feedback physician suggest
aggreg market grow come
endometriosi uterin fibroid
three gnrh antagonist view larg
undifferenti import aspect believ orilissa
keep first-to-market advantag physician emphas
heterogen respons patient popul
believ may abl carv nich real-world
experi gain orilissa comprehens data set
endometriosi uterin fibroid far neither relugolix
linzagolix demonstr superior efficaci orilissa base
compani inform svb leerink llc research
pleas refer page import disclosur price chart analyst certif
avail data furthermor orilissa like first-to-market
advantag indic year lead endometriosi
month lead uterin fibroid also benefit greater
resourc dispos physician indic much like
oral contracept market expect use avail option
class best fit patient need relugolix simpl
conveni dose regimen daili dose includ co-
hot flush discontinu due advers event uf relugolix
would ideal physician patient look conveni
predict efficaci safeti linzagolix flexibl dose
option without add-back would ideal physician
look tailor treatment individu patient base diseas
sever risk factor estim orilissa keep share
endometriosi uf due lead market relugolix
linzagolix take share respect given
differenti featur
myov ecast share risk-adjust sale base
input survey model peak market share relugolix uterin
fibroid endometriosi assumpt translat sale
sale sale use probability-of-success po uf
reflect industry-standard regulatori risk em await phase read-out
compar first order analyt consensu revenu uf endometriosi indic
forecast consensu consensu
consensu howev note consensu number may
skew outlier data point thu less reliabl
updat orilissa forecast base analysi
increas orilissa sale estim thru account greater market
share base posit result medacorp physician survey estim
decreas reflect lower termin gnrh market opportun due effect
treatment holiday reduc expect averag treatment durat months/year
months/year reduc forecast account mid-year loss exclus
orilissa updat orilissa sale estim repres reduct
compar prior estim reflect entri gener competit
increment cautiou outlook orilissa follow recent
earn call lower orilissa forecast reflect slower launch compani
downward revis sale guidanc current updat reflect
margin higher sale base recent physician survey revenu
outlook later year significantli lower base shorter treatment durat
smaller termin address market reason peak orilissa revenu forecast
lower earlier prior peak
impact valuat primarili due downward revis later year sale
overal impact total product sale forecast minim
ep estim remain unchang thru pt remain unchang although
dcf valuat slightli lower due lower long-term cash flow base adjust revenu
forecast reiter outperform rate compani stock
chang obsv sale forecast account gener orilissa competit pt
base input survey adjust launch trajectori linzagolix uterin
fibroid endometriosi linzagolix sale estim lower
lower higher risk-adjust sale
vs previous forecast peak market share linzagolix
two indic linzagolix revenu forecast consensu
consensu consensu also lower
linzagolix revenu gener orilissa could potenti enter
market compet brand gnrh antagonist well final adjust
total share outstand account potenti equiti rais period
price target obsv remain
price target per share stock rate outperform
establish independ pharmaceut compani transit new
phase term scale oper effici plan acquisit allergan earli
allergan bring new revenu market categori outsid
current product portfolio allergan esthet busi one endur franchis
industri unlik advers affect mani risk face tradit
necessarili fan consolid sake see bring
disciplin decis allergan portfolio confid maxim
valu allergan esthet busi cash flow without disrupt
effect busi unit innov cultur commerci effect ad
allergan dilut exposur humira posit offer
compani signific opportun oper effici synergi
alreadi disclos face mani challeng humira franchis rebat reform patent
challeng biosimilar pathway chang patent reform product cash flow
seem rel secur beyond two cornerston hematolog busi
grow strongli sever year least emerg combin neurosci
portfolio gener signific revenu posit cash flow earli
import pipelin program combin compani come upadacitinib
skyrizi venclexta imbruvica new indic signific increment opportun
probabl allergan neurolog migrain psychiatri schizophrenia program
boost back indic compani long sinc abandon
see combin compani deliv mid-singl digit revenu growth
high singl digit ep growth offer investor attract low doubl digit dividend growth
dividend yield today regard portfolio particularli
innov today view stock compel trade vehicl mid-to-high
reason post deal valuat rang
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani
mid-term growth tail risk celg averag
consensu ep multipl appli current ep estim
give valu use revenu multipl similar compani
consensu sale appli revenu estim give
valu lastli dcf valuat given wacc termin cash flow
growth rate begin humira biosimilar entri give present valu
averag three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
believ lead asset relugolix differenti approv market leader orilissa
favor toler conveni dose regimen gnrh
antagonist class believ novel class therapi provid uniqu treatment option
larg market patient endometriosi uterin fibroid estim
peak potenti given relugolix like enter market second
class could benefit market build effort forecast relugolix
could captur market share high gener risk-adjust sale
upsid could come relugolix uniqu product characterist simplifi
daili dose integr add-back therapi favor toler profil myovant
diversifi relugolix indic reli gnrh pathway prostat
cancer current model peak annual sale relugolix prostat cancer note
market potenti indic highli variabl depend myovant commerci
execut price chang physician current practic final myov target anoth
indic hormon axi assist reproduct current repres
upsid valuat current attribut littl valuat rate
myov outperform pt
pt base dcf forecast cash flow use discount
rate termin valu wacc rang phase compani
relugolix clinic data may interpret inferior competitor compar across
trial given differ primari endpoint relugolix conveni factor may view
meaning physician patient long-term treatment durat may shorter
market potenti gnrh class smaller expect myovant may abl chang
physician current practic treat prostat cancer
lead asset linzagolix look market among gnrh antagonist
believ novel class therapi provid uniqu treatment option larg market
patient endometriosi uterin fibroid obsv still gener risk-
adjust sale upsid could come linzagolix uniqu product characterist
add-back therapi flexibl daili dose indic lack food effect
believ market support multipl product class potenti best-in-class
profil view linzagolix captur gnrh antagonist market long term obsv
also nolasiban target grow high unmet need vitro fertil
ivf market current model peak annual risk-adjust sale nolasiban
repres total po approv peak commerci potenti final obsv
target anoth larg high unmet need market pre-term labor repres
upsid valuat current attribut littl valuat rate
obsv outperform pt
pt base dcf analysi forecast cash flow use
discount rate termin valu wacc rang phase
compani coverag univers myov itrm
risk valuat includ unsuccess regulatori action linzagolix nolasiban and/or
data readout linzagolix may less competit elagolix relugolix elagolix
head start may preclud uptak linzagolix current expect food effect
add-back therapi flexibl advantag may reson physician potenti
restrict payer environ gnrh antagonist class long-term safeti class may
turn wors current expect nolasiban live birth rate lbr data confirmatori
phase trial may posit
physician survey would use oral gnrh antagonist interest prescrib
drug class endometriosi uterin fibroid patient even higher
 diagnos patient endometriosi uterin fibroid consid moderate-to-sever symptom
sever pain bleed respect
 vast major respond interest use gnrh antagonist physician indic would use
class front line endometriosi uterin fibroid
 endometriosi physician deem frontlin patient later line patient good candid gnrh
antagonist uterin fibroid physician deem frontlin patient later line patient good candid
gnrh antagonist
stage physician perceiv three gnrh antagonist larg undifferenti expect orilissa
maintain major share like first-to-market entri posit
 efficaci safeti payer coverag top factor consider interestingli chang bone miner densiti bmd
need add-back therapi less import
 three gnrh antagonist perceiv larg undifferenti factor identifi import
suggest us sale market payer coverag play major role adopt addit follow-up
convers physician indic patient respons tend heterogen across patient expect use
three treatment prescrib treatment best meet patient need
 survey respons suggest share orilissa share relugolix linzagolix
respond indic payer coverag signific hurdl adopt note cumbersom
 vast major respond cite oral contracept and/or non-steroid anti-inflammatori drug nsaid requir step
therapi orilissa requir
 surprisingli respond said seen payer requir prior failur gnrh agonist lupron depot etc
approv orilissa report payer requir document failur oral contracept nsaid gnrh agonist
 market model assum endometriosi patient moderate-to-sever pain met payer requir
elig receiv gnrh antagonist
endometriosi base survey result estim
 respond anticip prescrib gnrh antagonist endometriosi patient moderate-to-sever pain
grow peak market model assum peak penetr overal penetr entir
patient popul repres survey result account sampl bia survey
 respond averag expect use gnrh antagonist month initi treatment cours median month
 respond expect patient treat gnrh antagonist recur symptom initi treatment cours
expect receiv treatment gnrh antagonist market model assum gnrh-
respond non-respond retreat class
 assum treatment durat month low dose month high dose orilissa initi expect
durat low dose gradual increas month physician gain experi long-term efficaci
uterin fibroid base survey result estim
 respond anticip prescrib gnrh antagonist uterin fibroid patient heavi mensur bleed
grow peak market model assum peak penetr overal penetr entir
patient popul repres survey result account sampl bia survey
 respond averag expect use gnrh antagonist month initi treatment cours median month
 respond expect patient treat gnrh antagonist recur symptom initi treatment cours
expect receiv treatment gnrh antagonist market model assum gnrh-
respond non-respond retreat class drug holiday month treatment
cours indefinit instead certain number cycl
 assum treatment durat month initi gradual increas month physician gain experi
long-term efficaci safeti perform
patient per month use orilissa patient
survey respond see averag median
endometriosi patient per month
survey respond good represent
treat averag median patient
medacorp survey endometriosi uterin fibroid june svb leerink research
diagnos endometriosi patient experi moderate-
physician estim averag endometriosi patient
respond estim
endometriosi patient
result consist
assumpt use market model
wherein assum us
endometriosi preval pool
medacorp survey endometriosi uterin fibroid june svb leerink research
vast major respond interest use gnrh
antagonist interest use frontlin
respond would use gnrh antagonist
frontlin set endometriosi
physician commun privat practic
will use gnrh antagonist
respond indic would limit use gnrh antagonist vast
major would use either up-front one line prior therapi oral contracept non-
ask would prior therapi gnrh antagonist use set physician list surgeri
depo-provera lupron intra-uterin devic laparoscopi found interest
physician note gnrh antagonist would consid post surgeri believ current
practic physician prefer surgic diagnosi prior use lupron howev better appreci
safeti profil class would expect practic chang
respons gener consist across physician differ practic set respond
commun privat practic will use gnrh antagonist draw strong conclus
correspond feedback interview attribut sampl size survey
medacorp survey endometriosi uterin fibroid june svb leerink research
frontlin endometriosi patient half later line
patient deem candid gnrh antagonist
per respond basi physician expect patient elig gnrh antagonist
per respond basi physician expect averag endometriosi patient elig
gnrh antagonist patient elig respect
respons gener consist across physician differ practic set respond
commun privat practic gener defin good candid gnrh antagonist
typic see less sever patient
medacorp survey endometriosi uterin fibroid june svb leerink research
respond physician bullish penetr gnrh
antagonist endometriosi
averag respond expect give oral gnrh
antagonist endometriosi patient
moderate-to-sever pain peak
endometriosi patient moderate-to-
sever pain patient
peak
respond expect entri gener elagolix
expand penetr gnrh antagonist class
averag
caution due sampl bia respond
need given orilissa least patient
respons may reflect view earli adopt
evidenc trend orilissa actual
penetr class like lower ramp
also like slower
assum penetr gnrh-elig patient
ramp
peak assumpt gnrh-respond
retreat class discuss later
medacorp survey endometriosi uterin fibroid june svb leerink research
physician gener satisfi orilissa efficaci safeti
treatment burden rais issu insur coverag
physician gener satisfi orilissa efficaci safeti treatment burden rais issu
insur coverag
safeti toler
medacorp survey endometriosi uterin fibroid june svb leerink research
step therapi requir mani payer includ oral contracept
nsaid surprisingli gnrh agonist
payer requir orilissa use oral contracept
and/or nsaid also requir prior gnrh agonist
fail
averag respond estim good candid
candid gnrh antagonist payer requir
medacorp survey endometriosi uterin fibroid june svb leerink research
vast major respond cite oral
drug nsaid requir step therapi
orilissa requir
surprisingli respond said
seen payer requir prior failur gnrh
agonist lupron depot etc approv
orilissa report payer requir
document failur oral contracept
nsaid gnrh agonist approv orilissa
requir includ prior treatment
depo-provera iud danazol dexa
bmd diagnosi surgeri
respond seen payer
requir far
proport good candid gnrh
antagonist also meet payer
requir rang wide
respons averag
market model assum
endometriosi patient moderate-to-sever
pain met payer requir
elig receiv gnrh antagonist
increas time physician
payer better understand benefit gnrh
respond expect treatment durat shorter
label expect gradual increas
respond expect use gnrh antagonist
year averag treatment cours
second later treatment
contrari current label orilissa state max treatment durat
month low dose month high dose respond
averag expect use gnrh antagonist month initi treatment
averag respond expect patient treat gnrh
antagonist recur symptom initi treatment cours
expect receiv treatment gnrh antagonist
would expect higher believ viewpoint would
evolv experi class
respond expect wait averag month median month
restart treatment averag cycl
retreat rang median cycl number addit cycl
came lower uf howev upon follow-up
uncov good reason limit use
respond unwil retreat patient gnrh
market model assum gnrh-respond non-
respond retreat drug holiday month
treatment cours indefinit instead certain number cycl
patient like effect altern treatment option
assum treatment durat month low dose gradual
increas month month high dose orilissa
lead month per year weight averag basi split
weight drug holiday treatment cycl factor
assumpt averag complianc rate estim
equilibrium treatment durat orilissa month everi month
treatment durat relugolix linzagolix month
two come add-back high dose form like get longer
durat label
medacorp survey endometriosi uterin fibroid june svb leerink research
interestingli
presenc
absenc add-
back therapi
low list
efficaci safeti ex bmd payer coverag top factor
consider interestingli less import
respond rate efficaci safeti payer coverag import factor
efficaci
safeti
bmd
need
respond rate efficaci safeti payer coverag top factor
efficaci
safeti
bmd
flexibl dose need
medacorp survey endometriosi uterin fibroid june svb leerink research
three gnrh antagonist perceiv larg undifferenti
import factor
efficaci
safeti toler
bmd
bmd
need hormon
medacorp survey endometriosi uterin fibroid june svb leerink research
survey respons suggest share orilissa share mid-
relugolix linzagolix
survey respons suggest share orilissa share relugolix
ramp relugolix
model
share orilissa
relugolix linzagolix
respect equilibrium
state gener orilissa
linzagolix like slower
respond
expect enter
market year later
respect
expect share
orilissa quickli erod
gener launch
share relugolix
linzagolix also declin
respect
gener
relugolix linzagolix enter
market believ
gener take vast
major share leav
brand
medacorp survey endometriosi uterin fibroid june svb leerink research
month estim patient heavi menstrual bleed
survey respond see averag median
physician estim averag uf patient
heavi menstrual bleed
respond estim uf patient heavi menstrual bleed
result consist assumpt use model assum us uterin fibroid
preval pool heavi menstrual bleed
medacorp survey endometriosi uterin fibroid june svb leerink research
vast major respond will use gnrh antagonist
will use up-front uterin fibroid
respond will use gnrh antagonist
frontlin set uterin fibroid
physician commun privat practic
will use gnrh antagonist
surgeri
surgeri
respond want limit use gnrh antagonist vast major
will use either up-front one line prior therapi oral contracept nsaid
anoth respond expect use gnrh antagonist immedi surgeri
ask would prior therapi gnrh antagonist use set physician list surgeri
lupron intra-uterin devic laparoscopi lysteda clot
respons gener consist across physician differ practic set respond
commun privat practic will use gnrh antagonist
medacorp survey endometriosi uterin fibroid june svb leerink research
one-fourth frontlin uf patient third later line
patient deem candid gnrh antagonist
per respond basi physician expect patient elig gnrh antagonist
per respond basi physician expect averag uf patient elig gnrh
antagonist patient elig respect
proport respond will use gnrh antagonist treatment line uf
proport good candid gnrh antagonist uf patient lower endometriosi
potenti due less experi class uf
medacorp survey endometriosi uterin fibroid june svb leerink research
respond physician less bullish penetr gnrh
antagonist uf endometriosi
averag respond expect give oral gnrh
antagonist uterin fibroid patient
moderate-to-sever pain peak
respond anticip give oral gnrh antagonist
uterin fibroid patient heavi menstrual
bleed patient
peak
respond expect entri gener elagolix
expand penetr gnrh antagonist class
averag
caution due sampl bia respond
need given orilissa least patient
respons may reflect view earli adopt
evidenc trend orilissa actual
penetr class like lower ramp
also like slower
assum penetr gnrh-elig patient
ramp
peak assumpt gnrh-respond
retreat class discuss later
medacorp survey endometriosi uterin fibroid june svb leerink research
respond expect treatment durat consist trial
expect gradual increas
respond expect use gnrh antagonist
year averag treatment cours
second later treatment
although label lupron depot limit treatment durat
month present data orilissa treatment
year respond averag expect use gnrh antagonist
month initi treatment cours median month
averag respond expect patient treat gnrh
antagonist recur symptom initi treatment
cours expect receiv treatment
gnrh antagonist
respond expect wait averag month median
month restart treatment averag
cycl retreat rang median cycl
respond unwil retreat patient
market model assum gnrh-respond
non-respond retreat drug holiday month
treatment cours indefinit instead certain number
cycl patient like effect altern
assum treatment durat month initi gradual
increas month physician gain experi
long-term efficaci safeti perform three product carri
add-back could allow longer durat label
treatment durat month lead month per year
equilibrium drug holiday treatment cycl
factor
assumpt averag complianc rate estim
equilibrium treatment durat month everi month
medacorp survey endometriosi uterin fibroid june svb leerink research
efficaci safeti payer coverag remain top factor
respond deem import uf
respond rate efficaci safeti payer coverag import factor
efficaci
efficaci
safeti
need
bmd
respond rate efficaci safeti payer coverag top factor
efficaci
efficaci
safeti
need
bmd
medacorp survey endometriosi uterin fibroid june svb leerink research
three gnrh antagonist perceiv larg undifferenti
import factor
efficaci reduc
efficaci
safeti toler
bmd
bmd
need
medacorp survey endometriosi uterin fibroid june svb leerink research
survey respons suggest share orilissa share mid-
relugolix linzagolix
survey respons suggest share orilissa share relugolix
ramp relugolix
model
share orilissa
relugolix linzagolix
respect equilibrium
state gener orilissa
linzagolix like faster
endometriosi
enter market
year year later
respect
expect share
orilissa quickli erod
gener launch
share relugolix
linzagolix also declin
respect
gener
relugolix linzagolix enter
market believ
gener take vast
major share leav
brand
medacorp survey endometriosi uterin fibroid june svb leerink research
uterin fibroid endometriosi repres multi-billion dollar
women reproduct age
women reproduct age
women endometriosi
women diagnos uf
women diagnos endometriosi
uf patient heavi menstrual bleed
endometriosi patient moderate-to-
uf patient treat heavi
well control oral
well control oral
restructur endometriosi market model account real-world
treat
patient
gnrh
gnrh
insight introduc
gnrh-nave popul
take haircut report
respons rate weight averag
low high dose account
differ trial popul
half survey respons
indic payer requir failur
lupron approv gnrh antagonist
everi respond kept
drug kol talk survey
suggest determin whether
re-treat patient
gnrh antagonist
given heterogen patient
respons given gnrh
antagonist physician expect cycl
gnrh antagonist
believ treatment rate
respons rate would lower
respond popul
total patient treatment
medacorp kol interview medacorp survey endometriosi uterin fibroid june svb leerink research
restructur uterin fibroid market model account real-world
treat
patient
gnrh
gnrh
insight introduc
gnrh-nave popul
take haircut report
respons rate account
differ trial popul
half survey respons
indic payer requir failur
lupron approv gnrh antagonist
everi respond kept
drug kol talk survey
suggest determin whether
re-treat patient
gnrh antagonist
given heterogen patient
respons given gnrh
antagonist physician expect cycl
gnrh antagonist
believ treatment rate
respons rate would lower
respond popul
total patient treatment
medacorp kol interview medacorp survey endometriosi uterin fibroid june svb leerink research
popul million
women million
reproduct age
women reproduct age million
endometriosi
patient endometriosi
patient moderate-to-sever pain
patient treat moderate-to-sever pain
control contraceptives/nsaid
candid gnrh antagonist
gnrh antagonist-nav patient treat
gnrh antagonist-nav
treat gnrh antagonist
gnrh antagonist respond retreat
gnrh antagonist-experienc
recur symptom
re-treat gnrh antagonist
gnrh antagonist non-respond retreat
non-respond patient treat previous
non-respond patient treat current year
re-treat gnrh antagonist
respond gnrh antagonist
total pay patient treatment
total patient moderate-to-sever pain
ex-u sale us sale
popul million
women million
reproduct age
women reproduct age million
diagnos uterin fibroid
patient diagnos uterin fibroid
patient heavi menstrual bleed
patient heavi menstrual bleed
patient treat
patient treat
control iud/contraceptives/nsaid
candid gnrh antagonist
gnrh antagonist-nav patient treat
gnrh antagonist-nav
treat gnrh antagonist
gnrh antagonist respond retreat
gnrh antagonist-experienc
recur symptom
re-treat gnrh antagonist
gnrh antagonist non-respond retreat
non-respond patient treat previous
non-respond patient treat current year
re-treat gnrh antagonist
respond gnrh antagonist
total patient treat gnrh antagonist
total pay patient treatment
total patient heavi menstrual bleed
ex-u sale us sale
endometriosi uterin fibroid
number respond
respons repres averag aggreg respons unless otherwis note
screener follow best describ specialti
gynecolog
obstetr
screener mani endometriosi patient see month
number endometriosi patient see per month mean
number endometriosi patient see per month median
number endometriosi patient see per month
screener mani endometriosi patient treat orilissa
number endometriosi patient treat orilissa mean
number endometriosi patient treat orilissa median
number endometriosi patient treat orilissa
screener mani uterin fibroid patient see month
number uterin fibroid patient see month mean
number uterin fibroid patient see month median
number uterin fibroid patient see month
screener familiar phase data relugolix linzagolix
familiar data
heard familiar data
heard
best describ affili center
percent endometriosi patient see moderate-to-sever pain
percent endometriosi patient see moderate-to-sever pain
set would use oral gnrh antagonist check appli
patient fail oral contracept nsaid
patient fail oral contracept nsaid and/or therapi surgeri depo-provera
hormon progestin provera
percent endometriosi patient treatment would deem suitabl oral gnrh antagonist
percent endometriosi patient consid candid oral gnrh antagonist
percent treatment
percent treatment
percent treatment
percent patient endometriosis-associ moderate-to-sever pain anticip give oral gnrh
would rate orilissa follow aspect pleas rate scale poor
safeti toler
experi current requir payer cover orilissa check appli
pleas specifi iud diagnos surgeri fail danazol fail depo-provera
fail dmpa pre auth dexa complet eval fda contraind
list packag insert
proport patient believ candid oral gnrh antagonist met payer requir
percent patient candid oral gnrh antagonist approv orlissa
accord clinic requir
long month give patient oral gnrh antagonist assum similar profil orilissa
initi treatment cours number month
second later treatment cours number month
percent patient treat gnrh antagonist endometriosi expect initi respond
recur symptom stop treatment
percent patient recur symptom stop gnrh treatment
percent endometriosi patient treat gnrh antagonist initi respond recur
symptom stop treatment would re-treat gnrh antagonist
percent endometriosi patient re-treat gnrh antagonist
mani month stop initi round treatment would restart treatment
number month stop initi round treatment would restart treatment mean
number month stop initi round treatment would restart treatment median
number month stop initi round treatment would restart treatment
mani round treatment would treat gnrh antagonist
round would treat gnrh antagonist
pleas rank follow factor order import consid gnrh antagonist prescrib
endometriosi
import
efficaci reduc pain
safeti toler bone miner densiti bmd
side effect bmd
flexibl dose regimen differ patient characterist
need hormon add-back therapi
payer coverage/out-of-pocket cost patient
avail dose regimen test phase
need hormon add-back therapi
add-back test clinic trial requir label howev higher dose approv use
month wherea lower dose approv use month
compani press releas present orilissa label maclean et al clin endocrinol metab
three oral gnrh antagonist rate follow factor poor excel
efficaci reduc pain
safeti toler bone miner densiti bmd
side effect bmd
flexibl dose regimen differ patient characterist
need hormon add-back therapi
assum relugolix get fda approv linzagolix approv percent endometriosi
patient receiv oral gnrh antagonist expect give follow drug
gener orilissa enter market assum percent endometriosi patient receiv oral gnrh
antagonist expect give follow drug
entri gener orilissa impact percentag patient endometriosis-associ moderate-to-sever pain
expect give oral gnrh antagonist
gener orilissa increas proport patient endometriosi associ moderate-to-sever
pain give oral gnrh antagonist
chang proport patient oral gnrh antagonist
overal increas orilissa
proport uf patient see heavi menstrual bleed menstrual blood loss
percent uterin fibroid patient see heavi menstrual bleed
set would use oral gnrh antagonist check appli
patient fail oral contracept nsaid
patient fail oral contracept nsaid and/or therapi surgeri iud
laparoscopi iud hormon lupron lysteda otc hormon treatment
medic
immedi prior surgic therapi
proport uf patient would deem suitabl oral gnrh antagonist
percent uterin fibroid patient consid candid oral gnrh antagonist
percent treatment
percent treatment
percent treatment
assum orilissa get fda approv late earli percent patient uf-associ heavi
menstrual bleed anticip give oral gnrh antagonist
immedi upon launch
long month give patient oral gnrh antagonist assum similar profil orilissa
initi treatment cours number month
second later treatment cours number month
percent patient treat gnrh antagonist uterin fibroid expect initi respond
recur symptom stop treatment
percent uf patient recur symptom stop gnrh treatment
percent uterin fibroid patient treat gnrh antagonist initi respond recur
symptom stop treatment would re-treat gnrh antagonist
percent uterin fibroid patient re-treat gnrh antagonist
soon stop initi round treatment would restart treatment
number month stop initi round treatment would restart treatment mean
number month stop initi round treatment would restart treatment median
number month stop initi round treatment would restart treatment
mani round treatment would treat gnrh antagonist
round would treat gnrh antagonist mean
round would treat gnrh antagonist median
round would treat gnrh antagonist
pleas rank follow factor order import consid gnrh antagonist prescrib uf-
associ heavi menstrual bleed
import
efficaci reduc menstrual bleed
efficaci reduc pain
safeti toler bone miner densiti bmd
side effect bmd
flexibl dose regimen differ patient characterist
need hormon add-back therapi
payer coverage/out-of-pocket cost patient
avail dose regimen test phase bid
need hormon add-back therapi
option dose
compani press releas present orilissa label maclean et al clin endocrinol metab
three oral gnrh antagonist rate follow factor poor excel
efficaci reduc menstrual bleed
efficaci reduc pain
safeti toler bone miner densiti bmd
side effect bmd
flexibl dose regimen differ patient characterist
need hormon add-back therapi
assum orilissa get fda approv late earli relugolix get fda approv linzagolix
approv percent uf patient receiv oral gnrh antagonist expect give follow
gener orilissa enter market assum percent uf patient receiv oral gnrh antagonist
expect give follow drug
entri gener orilissa impact percentag patient uf-associ heavi menstrual bleed
expect give oral gnrh antagonist
gener orilissa increas proport patient uf-associ heavi menstrual bleed
give oral gnrh antagonist
chang proport patient oral gnrh antagonist
overal increas gener orilissa
background efficaci gnrh antagonist endometriosi
orilissa elagolix elari elari phase trial
endpoint percentag women pain reduct dysmenorrhea decreas stabl use rescu
respons rate month
respons rate month
respons rate month
respons rate month
endpoint percentag women pain reduct non-menstru pelvic pain decreas stabl use
respons rate month
respons rate month
respons rate month
respons rate month
relugolix phase trial
endpoint chang baselin patient-report pain score last day first week studi
measur mean visual analogu score va mm
chang overal pelvic pain
chang dysmenorrhea
note dose taken phase develop box
linzagolix edelweiss phase trial
respond week
respond week
respond week
respond week
respond week
respond week
compani press releas present taylor et al engl
background efficaci gnrh antagonist uterin fibroid
orilissa elagolix elari elari phase trial
endpoint women menstrual blood loss volum less ml month greater
reduct menstrual blood loss volum baselin month
relugolix liberti phase trial
endpoint women menstrual blood loss volum less ml last day
greater reduct menstrual blood loss volum baselin month
relugolix phase trial japan
endpoint percent women decreas blood loss pictori blood loss assess chart
week week
relugolix phase trial japan
endpoint percent women maximum pain score day final dose
linzagolix phase trial
endpoint percent day bleed treatment period
percent day bleed
note dose taken phase develop box
compani press releas present
background safeti gnrh antagonist
orilissa elagolix elari elari phase trial endometriosi
ad lead discontinu
relugolix liberti phase trial uterin fibroid
seriou ae relat drug
ae lead discontinu
linzagolix edelweiss phase trial endometriosi
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
phase trial reuslt newly-diagnos
supplementari approv cll result front-
phase trial front-lin aml
svb leerink llc research compani file
analysi stock price svb leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep celg
svb leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current svb leerink dcf marketed/l stage program
sourc svb leerink llc estim compani file factset
brand
type event
event trial detail
date known
up/down
expect
svb leerink llc equiti research compani file
number except per share data
number except per share data
revenu uf
revenu endometriosi
revenu prostat cancer
number except per share data
prepaid expens current asset
furnitur fixtur equip pp
current matur long-term debt
payabl current liabil
accumul comprehens incom
number except per share data
adjust reconcil ni net cash oper
amort debt discount issuanc cost
purchas in-process research develop expens
chang fair valu warreant liabil
increas /decreas receiv
increas /decreas long term-asset
increas payabl current liabil
decreas increas work capit
chang account receiv
chang prepaid expens asset
chang inventori
chang account payabl
chang accru expens
use rental deposit
payment plant equip
acquisit licens
net invest
proce issu share equiti secur
payment share issuanc cost
proce debt financ net financ cost
transact roivant
net financ
net chang equival restrict
net chang restrict
net chang equival
effect exchang rate chang cash cash equival
brand
type event
event trial detail
date known
up/down
expect
result implant trial
addit fda feedback implant trial
primari endpoint data primros trial
primari endpoint data primros trial
phase iia prolong interim data first
svb leerink llc equiti research compani file
number except per share data
revenu uf
revenu endometriosi
prepaid expens current asset
furnitur fixtur equip pp
payabl current liabil
current portion long-term debt
adjust reconcil ni net cash oper
increas /decreas receiv
increas /decreas prepaid expens defer cost long term-asset
increas payabl current liabil
increas accru expens
decreas increas work capit
use rental deposit
payment plant equip
acquisit licens
net invest
proce issu share equiti secur
payment share issuanc cost
proce issuanc debt
payment defer cost financ activ
net financ
net chang equival
effect exchang rate chang cash cash equival
